Big idea: Using its patented molecules, Intronn is trying to repair genetic mutations by splicing special instructions to RNA.
Web site: www.intronn.com
Who's in charge: Gerard J. McGarrity, president and chief executive; Nancy Streicher, vice president of finance & administration.
Funding: $15 million total from AEA Investors LLC, Research Corporation Technologies Inc., Proteome Sciences PLC.
Employees: About 15.
Partners and collaborators: National Cancer Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, Stanford University, Kings College London, Mount Sinai School of Medicine, University of Iowa .
Origin of company name: Long non-coding sequences in genes are called introns.